In mice given dexamethasone (20 mg/kg for 12 days) to induce muscle wasting, a 4-week ladder-climbing resistance program restored muscle morphology and fatigue resistance. Cannabigerol (CBG, 10 mg/kg i.p. on training days) did something different: it raised power output by about 55% after one week and up to 87% after four weeks versus exercise alone, increased peak grip strength roughly 10%, and cut post-exercise blood lactate about 48% in sedentary animals. Fiber cross-sectional area rose only slightly.
The notable signal is the dissociation between structure and function. Exercise rebuilt muscle; CBG appeared to improve how the nervous system drives it. That fits the idea that sarcopenia is as much neuromuscular as muscular, yet drug candidates almost always target mass. Caution is essential, though. This is a mouse study in a glucocorticoid-injury model, which differs from age-related sarcopenia. The intraperitoneal dosing has no established human equivalent, and the lower lactate could reflect altered metabolism or reduced effort rather than a true benefit. No human data support CBG for muscle health, and over-the-counter cannabinoid products vary widely in purity and dose. Adults worried about age-related muscle loss should rely on what is proven: progressive resistance training and adequate protein. Editorially, this is early-stage and hypothesis-generating, an interesting mechanistic lead that needs replication in aged animals, oral dosing, and eventually controlled human trials before it means anything for practice.